David D Dore

Summary

Affiliation: Cancer Prevention Program
Country: USA

Publications

  1. ncbi Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial
    David D Dore
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Ann Intern Med 150:9-18. 2009
  2. ncbi Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
    David D Dore
    i3 Drug Safety, 950 Winter Street, Waltham, MA 02451, USA
    Curr Med Res Opin 25:1019-27. 2009
  3. ncbi Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction
    David D Dore
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Pharmacotherapy 29:775-83. 2009
  4. ncbi Atypical antipsychotic use and risk of fracture in persons with Parkinsonism
    David D Dore
    i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, Massachusetts, USA
    Mov Disord 24:1941-8. 2009
  5. ncbi Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users
    David D Dore
    i3 Drug Safety, Waltham, MA 02451, USA
    Contraception 81:408-13. 2010
  6. ncbi Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus
    David D Dore
    i3 Drug Safety, Waltham, MA 02451, USA
    Pharmacoepidemiol Drug Saf 20:209-13. 2011
  7. ncbi A cohort study of acute pancreatitis in relation to exenatide use
    D D Dore
    i3 Drug Safety, Waltham, MA, USA
    Diabetes Obes Metab 13:559-66. 2011
  8. ncbi Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality
    David D Dore
    Departments of Health Services, Policy and Practice and Epidemiology, Program in Public Health, The Warren Alpert Medical School of Brown University, Providence, RI, USA
    Pharmacoepidemiol Drug Saf 21:29-36. 2012
  9. ncbi Telithromycin use and spontaneous reports of hepatotoxicity
    David D Dore
    Department of Community Health, Brown Medical School, Providence, RI 02903, USA
    Drug Saf 30:697-703. 2007

Detail Information

Publications9

  1. ncbi Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial
    David D Dore
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Ann Intern Med 150:9-18. 2009
    ..Recent evidence suggests that statins may prevent cancer...
  2. ncbi Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
    David D Dore
    i3 Drug Safety, 950 Winter Street, Waltham, MA 02451, USA
    Curr Med Res Opin 25:1019-27. 2009
    ....
  3. ncbi Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction
    David D Dore
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Pharmacotherapy 29:775-83. 2009
    ....
  4. ncbi Atypical antipsychotic use and risk of fracture in persons with Parkinsonism
    David D Dore
    i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, Massachusetts, USA
    Mov Disord 24:1941-8. 2009
    ..2-2.4) was associated with a higher rate of fracture. Use of an AA was associated with a higher rate of fracture in persons with parkinsonism. Prescribers must be cautious when using these agents in elderly persons with parkinsonism...
  5. ncbi Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users
    David D Dore
    i3 Drug Safety, Waltham, MA 02451, USA
    Contraception 81:408-13. 2010
    ..We extended an earlier study that found a twofold higher risk of venous thromboembolism (VTE) associated with the transdermal contraceptive system relative to norgestimate-containing oral contraceptives (NGM-OC)...
  6. ncbi Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus
    David D Dore
    i3 Drug Safety, Waltham, MA 02451, USA
    Pharmacoepidemiol Drug Saf 20:209-13. 2011
    ..To estimate the positive predictive value (PPV) of claims for acute pancreatitis among initiators of antihyperglycemic drugs in commercial health insurance claims data...
  7. ncbi A cohort study of acute pancreatitis in relation to exenatide use
    D D Dore
    i3 Drug Safety, Waltham, MA, USA
    Diabetes Obes Metab 13:559-66. 2011
    ..Reports of acute pancreatitis associated with exenatide treatment prompted this study to estimate the association between acute pancreatitis and exenatide use relative to other antihyperglycaemic drugs...
  8. ncbi Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality
    David D Dore
    Departments of Health Services, Policy and Practice and Epidemiology, Program in Public Health, The Warren Alpert Medical School of Brown University, Providence, RI, USA
    Pharmacoepidemiol Drug Saf 21:29-36. 2012
    ..Our objective was to evaluate routinely collected cancer clinical data for adjustment of confounding using an example evaluation of mortality associated with aromatase inhibitors and tamoxifen...
  9. ncbi Telithromycin use and spontaneous reports of hepatotoxicity
    David D Dore
    Department of Community Health, Brown Medical School, Providence, RI 02903, USA
    Drug Saf 30:697-703. 2007
    ..Recent reports have described cases of telithromycin-related hepatotoxicity. The objective of this study is to quantify the effect of telithromycin use on the risk of hepatotoxicity...